KRAS and neoplasm: As illustrated in Figure 2, B and C, Kras ablation dramatically decreased tumor burden after 1 month of TMX exposure, reaching 65% CRs and 35% PRs, a result similar to that observed in the KG12VloxPC2 tumor model.